Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821892 | 0.84 | LMNA (0.60) | LMNAALDH1A1HTTNPC1KMT2A | |
| SCHEMBL10455773 | 0.80 | ALDH1A1 (0.50) | LMNAASAH1ALDH1A1HTTKMT2A | |
| SCHEMBL27460365 | 0.78 | CES2 (0.46) | KMT2AMEN1 | |
| SCHEMBL28536859 | 0.76 | LMNA (0.58) | LMNAALDH1A1HTTNPC1KMT2A | |
| SCHEMBL9057075 | 0.75 | ASAH1 (0.61) | ASAH1NR1H2NR1H3 | |
| SCHEMBL29257418 | 0.75 | TDP1 (0.54) | LMNAASAH1ALDH1A1NPC1KMT2A | |
| SCHEMBL30423475 | 0.75 | TDP1 (0.54) | LMNAASAH1ALDH1A1NPC1KMT2A | |
| SCHEMBL27572474 | 0.74 | ASAH1 (0.47) | LMNAASAH1ALDH1A1POLBNR1H2 | |
| SCHEMBL27455907 | 0.74 | L3MBTL1 (0.48) | LMNAALDH1A1HTTNPC1KMT2A | |
| SCHEMBL27455908 | 0.74 | L3MBTL1 (0.48) | LMNAALDH1A1HTTNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235082-A1 | Long-chain, straight-chain 2-amino-3-hydroxyalkanes | RINEHART KENNETH L | 2006-10-19 | — | — | US | disclosed |
| US-7109244-B2 | Compositions and methods comprising long-chain, straight-chain 2-amino-3-hydroxyalkanes | RINEHART KENNETH L | 2006-09-19 | — | — | US | disclosed |
| US-20060183806-A9 | COMPOSITIONS AND METHODS COMPRISING LONG-CHAIN, STRAIGHT-CHAIN 2-AMINO-3- HYDROXYALKANES | RINEHART KENNETH L | 2006-08-17 | — | — | US | disclosed |
| US-RE38793-E1 | Spisulosine compounds | RINEHART KENNETH L | 2005-09-06 | — | — | US | disclosed |
| EP-1069894-B1 | SPISULOSINE COMPOUNDS HAVING ANTITUMOUR ACTIVITY | UNIV ILLINOIS (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6800661-B1 | Spisulosine compounds | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2004-10-05 | — | — | US | disclosed |
| US-20040147615-A1 | Spisulosine compounds | RINEHART KENNETH L (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1069894-A1 | SPISULOSINE COMPOUNDS HAVING ANTITUMOUR ACTIVITY | The Board of Trustees for the University of Illinois (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6107520-A | SHOW UNIQUE CYTOTOXICITY AGAINST MURINE LYMPHOCYTIC LEUKEMIA CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-08-22 | — | — | US | disclosed |
| WO-1999052521-A1 | SPISULOSINE COMPOUNDS HAVING ANTITUMOUR ACTIVITY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235082-A1 | Long-chain, straight-chain 2-amino-3-hydroxyalkanes | SLC3A2, HACL2, CLSPN | LMNA 814/4885ASAH1 893/4885ALDH1A1 556/4885 |
| US-20040147615-A1 | Spisulosine compounds | CLSPN, SPIN3, OAT | LMNA 554/4885ASAH1 519/4885ALDH1A1 2109/4885 |
| US-20060183806-A9 | COMPOSITIONS AND METHODS COMPRISING LONG-CHAIN, STRAIGHT-CHAIN 2-AMINO-3- HYDROXYALKANES | NEFM, OAT, POLM | LMNA 273/4885ASAH1 790/4885ALDH1A1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.